Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study

Philip Keiser, Naiel Nassar

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

A retrospective electronic database study was conducted to determine any differences in time to virological failure and percent of virological failure among HIV-infected patients concurrently receiving H2-blockers versus patients not receiving these agents while receiving atazanavir (ATV)/ritonavir (r) or lopinavir (LPV)/r-containing antiretroviral treatment regimens. Data were culled from October 2003 (when ATV became commercially available) through February 2006. Virological failure was defined as (1) two plasma HIV-1 RNA levels >400 copies/mL after at least one HIV-1 RNA level below the level of detection or (2) failure to achieve an HIV-1 RNA <400 copies/mL within 24 weeks. Data from 267 ATV/r-treated patients who met the case definition were compared with data from 670 LPV/r-treated patients. Approximately 10% of the ATV/r group received concurrent H2-blockers when compared with 20% of the LPV/r group. Multivariate analysis showed no statistically significant differences regarding time to virological failure between or among the four subgroups, adjusting for differences in baseline characteristics (P = 0.79, log-rank test). At 750 days following treatment initiation, the proportion of patients not experiencing virological failure was 56% in the ATV/r-blocker subgroup, 48% in the ATV/r-alone subgroup, 45% in the LPV/r-alone subgroup and 42% in the LPV/r-blocker subgroup.

Original languageEnglish (US)
Pages (from-to)561-562
Number of pages2
JournalInternational Journal of STD and AIDS
Volume19
Issue number8
DOIs
StatePublished - Aug 2008
Externally publishedYes

Fingerprint

Lopinavir
Ritonavir
Histamine H2 Receptors
Observational Studies
HIV
Databases
HIV-1
RNA
Atazanavir Sulfate
Multivariate Analysis
Therapeutics

Keywords

  • Acid-reducing agents
  • Atazanavir
  • Complications
  • Drug interactions
  • H-blockers
  • Kaletra
  • Virologic failure

ASJC Scopus subject areas

  • Dermatology
  • Public Health, Environmental and Occupational Health
  • Microbiology (medical)
  • Immunology

Cite this

@article{e585a0a544734d18b0d8993d97b0b17a,
title = "Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study",
abstract = "A retrospective electronic database study was conducted to determine any differences in time to virological failure and percent of virological failure among HIV-infected patients concurrently receiving H2-blockers versus patients not receiving these agents while receiving atazanavir (ATV)/ritonavir (r) or lopinavir (LPV)/r-containing antiretroviral treatment regimens. Data were culled from October 2003 (when ATV became commercially available) through February 2006. Virological failure was defined as (1) two plasma HIV-1 RNA levels >400 copies/mL after at least one HIV-1 RNA level below the level of detection or (2) failure to achieve an HIV-1 RNA <400 copies/mL within 24 weeks. Data from 267 ATV/r-treated patients who met the case definition were compared with data from 670 LPV/r-treated patients. Approximately 10{\%} of the ATV/r group received concurrent H2-blockers when compared with 20{\%} of the LPV/r group. Multivariate analysis showed no statistically significant differences regarding time to virological failure between or among the four subgroups, adjusting for differences in baseline characteristics (P = 0.79, log-rank test). At 750 days following treatment initiation, the proportion of patients not experiencing virological failure was 56{\%} in the ATV/r-blocker subgroup, 48{\%} in the ATV/r-alone subgroup, 45{\%} in the LPV/r-alone subgroup and 42{\%} in the LPV/r-blocker subgroup.",
keywords = "Acid-reducing agents, Atazanavir, Complications, Drug interactions, H-blockers, Kaletra, Virologic failure",
author = "Philip Keiser and Naiel Nassar",
year = "2008",
month = "8",
doi = "10.1258/ijsa.2007.007275",
language = "English (US)",
volume = "19",
pages = "561--562",
journal = "International Journal of STD and AIDS",
issn = "0956-4624",
publisher = "SAGE Publications Ltd",
number = "8",

}

TY - JOUR

T1 - Time to virological failure with atazanavir/ritonavir and lopinavir/ritonavir, with or without an H2-receptor blocker, not significantly different in HIV observational database study

AU - Keiser, Philip

AU - Nassar, Naiel

PY - 2008/8

Y1 - 2008/8

N2 - A retrospective electronic database study was conducted to determine any differences in time to virological failure and percent of virological failure among HIV-infected patients concurrently receiving H2-blockers versus patients not receiving these agents while receiving atazanavir (ATV)/ritonavir (r) or lopinavir (LPV)/r-containing antiretroviral treatment regimens. Data were culled from October 2003 (when ATV became commercially available) through February 2006. Virological failure was defined as (1) two plasma HIV-1 RNA levels >400 copies/mL after at least one HIV-1 RNA level below the level of detection or (2) failure to achieve an HIV-1 RNA <400 copies/mL within 24 weeks. Data from 267 ATV/r-treated patients who met the case definition were compared with data from 670 LPV/r-treated patients. Approximately 10% of the ATV/r group received concurrent H2-blockers when compared with 20% of the LPV/r group. Multivariate analysis showed no statistically significant differences regarding time to virological failure between or among the four subgroups, adjusting for differences in baseline characteristics (P = 0.79, log-rank test). At 750 days following treatment initiation, the proportion of patients not experiencing virological failure was 56% in the ATV/r-blocker subgroup, 48% in the ATV/r-alone subgroup, 45% in the LPV/r-alone subgroup and 42% in the LPV/r-blocker subgroup.

AB - A retrospective electronic database study was conducted to determine any differences in time to virological failure and percent of virological failure among HIV-infected patients concurrently receiving H2-blockers versus patients not receiving these agents while receiving atazanavir (ATV)/ritonavir (r) or lopinavir (LPV)/r-containing antiretroviral treatment regimens. Data were culled from October 2003 (when ATV became commercially available) through February 2006. Virological failure was defined as (1) two plasma HIV-1 RNA levels >400 copies/mL after at least one HIV-1 RNA level below the level of detection or (2) failure to achieve an HIV-1 RNA <400 copies/mL within 24 weeks. Data from 267 ATV/r-treated patients who met the case definition were compared with data from 670 LPV/r-treated patients. Approximately 10% of the ATV/r group received concurrent H2-blockers when compared with 20% of the LPV/r group. Multivariate analysis showed no statistically significant differences regarding time to virological failure between or among the four subgroups, adjusting for differences in baseline characteristics (P = 0.79, log-rank test). At 750 days following treatment initiation, the proportion of patients not experiencing virological failure was 56% in the ATV/r-blocker subgroup, 48% in the ATV/r-alone subgroup, 45% in the LPV/r-alone subgroup and 42% in the LPV/r-blocker subgroup.

KW - Acid-reducing agents

KW - Atazanavir

KW - Complications

KW - Drug interactions

KW - H-blockers

KW - Kaletra

KW - Virologic failure

UR - http://www.scopus.com/inward/record.url?scp=49449091828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49449091828&partnerID=8YFLogxK

U2 - 10.1258/ijsa.2007.007275

DO - 10.1258/ijsa.2007.007275

M3 - Article

VL - 19

SP - 561

EP - 562

JO - International Journal of STD and AIDS

JF - International Journal of STD and AIDS

SN - 0956-4624

IS - 8

ER -